tetrahydrocurcumin has been researched along with Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alcantara, KP; Bulatao, BPI; Muangnoi, C; Nalinratana, N; Rojsitthisak, P; Sorasitthiyanukarn, FN; Truong, TH; Vajragupta, O | 1 |
| Cao, HR; Fan, PH; Gao, XM; Kang, N; Lv, YH; Qiu, F; Wang, MM; Wang, YH; Yang, Y; Zhang, ZN | 1 |
2 other study(ies) available for tetrahydrocurcumin and Breast Neoplasms
| Article | Year |
|---|---|
Chitosan-coated nanostructured lipid carriers for transdermal delivery of tetrahydrocurcumin for breast cancer therapy.
Topics: Breast Neoplasms; Chitosan; Curcumin; Drug Carriers; Female; Humans; Lipids; Nanostructures; Particle Size | 2022 |
Tetrahydrocurcumin induces G2/M cell cycle arrest and apoptosis involving p38 MAPK activation in human breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Division; Curcumin; Enzyme Activation; G2 Phase; Humans; MCF-7 Cells; p38 Mitogen-Activated Protein Kinases | 2014 |